Episodios

  • Financial Incentives to Improve Cardiac Rehab Participation
    Jul 2 2024

    Individuals from lower socioeconomic status (SES) backgrounds face heightened risks of morbidity and mortality, particularly in the context of health conditions such as cardiovascular disease. Despite this increased vulnerability, they often face barriers to accessing crucial secondary prevention programs, such as cardiac rehabilitation. How can we bridge this gap and ensure that these vulnerable patients receive the support they urgently need?

    In this interview, Diann Gaalema, PhD and Anthony N. DeMaria, MD, MACC discuss financial incentives to improving cardiac rehab participation.

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    Más Menos
    10 m
  • Inpatient Initiation of HF GDMT: What Are You Waiting For?
    Jun 25 2024

    In this interview, Stephen Greene, MD, FACC and Sidney C. Smith Jr., MD, MACC discuss inpatient initiation of HF GDMT.

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    Más Menos
    13 m
  • Plaque Burden, Morphology and Flow – Beyond the Lumen
    Jun 18 2024

    Why should we assess plaque burden beyond luminal narrowing for cardiac prevention?

    In this interview, Andrew Choi, MD, FACC and Clyde W. Yancy, MD, MSc, MACC discuss insights from data and studies involving plaque burden, morphology and flow.

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    Más Menos
    13 m
  • Natural History of Bicuspid and Aneurysm-Associated Aortic Valve Disease
    Jun 11 2024

    The most common congenital heart defect, congenital BAV, affects 1% of the population (2% in men, 0.5% in women), with a male-to-female ratio of 2:1 to 3:1. It's characterized by diverse phenotypic expressions and outcomes, falling into two prognostic groups:

    1. Typical valvulo-aortopathy: Most common, with progressive BAV dysfunction and/or aorta dilatation but long-term survival similar to the general population.

    1. Complex valvulo-aortopathy: Associated with significant concomitant disorders and/or accelerated valvulo-aortopathy, leading to inferior long-term survival.

    BAV is a lifelong clinical condition with a morbidity burden exceeding 80%. Common complications include progression to ≥ moderate AS or AR, native aortic valve surgery, aortic aneurysm, surgery for aortic aneurysm, surgery for coarctation of the aorta, infective endocarditis, and aortic dissection.

    In this interview, Hector I. Michelena, MD, FACC and W. Douglas Weaver MD, MACC discuss the history of and complications associated with bicuspid valvuloaortopathy.

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    Más Menos
    12 m
  • Hey Doc, There's Calcium In My Coronaries⋯ Now What?
    Jun 4 2024

    Discover how detection of coronary artery calcium can greatly enhance risk prediction and risk mitigation, making it a critical tool for clinicians aiming to personalize patient care and prevent future cardiac events.

    In this interview, Michael D. Shapiro, DO, FACC and Roger S. Blumenthal MD, FACC explore CAC scoring and the role of calcium detection in tailoring patient care, personalized risk assessment, and the prevention of future cardiac events.

    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

    Más Menos
    10 m
  • The Hormone Puzzle: Decoding the what, when and how long of hormone replacement therapy in women
    May 28 2024

    In this interview, Leslie Cho, MD, FACC, and Steven E. Nissen MD, MACC explore the nuances of estrogen and testosterone replacement: who benefits, when to consider it, and how long it should last.

    Subscribe to ACCEL

    Más Menos
    11 m
  • Ultimate DAPT Trial Principal Results - Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding
    May 21 2024

    Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.

    In this interview, Gregg W Stone MD, FACC and Anthony N. DeMaria MD, MACC discuss principal results from the Ultimate DAPT Trial.

    Subscribe to ACCEL Lite

    Other ACC resources on DAPT and bleeding risk:

    1. One-Month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes - IVUS-ACS/ULTIMATE-DAPT

    2. Study Suggests Most Patients with Acute Coronary Syndromes Can Safely Stop Aspirin One Month After Percutaneous Coronary Intervention

    3. ACC.24 Presentation Slides | ULTIMATE-DAPT

    Más Menos
    12 m
  • Be Active RCT: Gamification & Financial Incentives to Increase Physical Activity
    May 14 2024

    The Be Active trial demonstrates the efficacy of scalable interventions, incorporating remote monitoring and behavioral economics, in boosting physical activity among high-risk cardiovascular patients. Lasting effects were observed even six months post-intervention. While additional data may be warranted for some stakeholders, these interventions hold promise as integral components of exercise-based prevention strategies for cardiovascular disease.

    In this interview, Alexander Fanaroff, MD, MHS and Glenn A. Hirsch MD, MHS, FACC discuss results from the Be Active RCT.

    Subscribe on Apple Podcasts |

    Más Menos
    10 m